Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients (Q38876395)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 June 2016

Language	Label	Description	Also known as
English	Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients	scientific article published on 24 June 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Dominique C Valla

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Gabriel Perlemuter

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Dominique Guyader

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Barbara Saba

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Cécile Batailler

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Kevin Moore

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

24 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

877-888

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine in the treatment of seasonal affective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Major depressive disorder, sleep EEG and agomelatine: an open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Antidepressant short-term and long-term brain effects during self-referential processing in major depression

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Antidepressant-induced liver injury: a review for clinicians

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

A retrospective pooled analysis of duloxetine safety in 23,983 subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Epidemiology of idiosyncratic drug-induced liver injury

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Transaminase elevation on placebo during phase I trials: prevalence and significance

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Nonalcoholic fatty liver disease: from pathogenesis to patient care.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Current concepts of mechanisms in drug-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Review article: drug-induced liver injury in clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

An official ATS statement: hepatotoxicity of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Idiosyncratic liver injury: challenges and approaches.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Agomelatine: fulminant liver failure in a patient with fatty liver

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Antidepressant-induced liver injury

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0351-6

21 January 2018

The safety of fluoxetine--an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/27342740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing fibrosis without a liver biopsy: are we there yet?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27342740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

1 reference

https://pubmed.ncbi.nlm.nih.gov/27342740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/27342740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-016-0351-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342740%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38876395&oldid=2202219859"